Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.

A wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), Sunovion was formed following the merger of DSP's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the life-affirming energy of the sun and the power of innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.

2011 | 2010 | 2009 | 2008 DSPA 2009 Press Releases

Date	Title
12/02/11	STEDESA™ Clinical Data Presented at 2011 American Epilepsy Society Annual Meeting
11/05/11	Sunovion's Investigational Ciclesonide Nasal Aerosol in an HFA Propellant, Demonstrated Positive Results in Patients with Perennial Allergic Rhinitis
10/27/11	LATUDA® (lurasidone HCl) Shown to be Non-Inferior to SEROQUEL XR® (quetiapine fumarate XR) in Risk for Relapse in a 12-Month, Double-Blind Extension Study of Adult Patients with Schizophrenia
10/17/11	Sunovion Pharmaceuticals Inc. Announces Partnership with CARE to Help Improve the Health and Lives of Those in Need
06/06/11	Sunovion Announces FDA Acceptance of New Drug Application for Ciclesonide HFA Nasal Aerosol
05/17/11	Latuda® (lurasidone HCl) was Associated with Low Rates of Weight Gain and Metabolic Changes in Patients with Schizophrenia in Data Presented at the 164th Meeting of the American Psychiatric Association
04/28/11	Everyone Breathe™ Launches New Asthma Education Grant Program to Raise Awareness of Asthma and Improve Asthma Care in Schools Across America
04/11/11	New STEDESA™ Clinical Data Presented at American Academy of Neurology Annual Meeting
03/22/11	Sunovion's Investigational Ciclesonide HFA Nasal Aerosol Effective in Treatment of Seasonal Allergic Rhinitis Symptoms
02/03/11	Once-daily Latuda® (lurasidone HCl) Now Available in Pharmacies Nationwide for the Treatment of Patients with Schizophrenia